Cargando…
Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
Survivin is responsible for cancer progression and drug resistance in many types of cancer. YM155 selectively suppresses the expression of survivin and induces apoptosis in cancer cells in vitro and in vivo. However, the mechanism underlying these effects of YM155 is unknown. Here, we show that a tr...
Autores principales: | Nakamura, Naoto, Yamauchi, Tomohiro, Hiramoto, Masashi, Yuri, Masatoshi, Naito, Masanori, Takeuchi, Masahiro, Yamanaka, Kentaro, Kita, Aya, Nakahara, Takahito, Kinoyama, Isao, Matsuhisa, Akira, Kaneko, Naoki, Koutoku, Hiroshi, Sasamata, Masao, Yokota, Hiroyuki, Kawabata, Shigeki, Furuichi, Kiyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Biochemistry and Molecular Biology
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394938/ https://www.ncbi.nlm.nih.gov/pubmed/22442257 http://dx.doi.org/10.1074/mcp.M111.013243 |
Ejemplares similares
-
Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010) -
Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
por: Blanco, Isabel, et al.
Publicado: (2023) -
The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
por: Xia, Hongping, et al.
Publicado: (2015) -
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016) -
Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment
por: Vay, Christian, et al.
Publicado: (2021)